The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
In the latest session, Bristol-Myers Squibb Co (NYSE: BMY) closed at $46.84 down -0.83% from its previous closing price of $47.23. In other words, the price has decreased by -$0.83 from its previous closing price. On the day, 15.85 million shares were traded.
Ratios:
For a deeper understanding of Bristol-Myers Squibb Co’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 8.09 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 7.28. For the most recent quarter (mrq), Quick Ratio is recorded 1.17 and its Current Ratio is at 1.28. In the meantime, Its Debt-to-Equity ratio is 2.95 whereas as Long-Term Debt/Eq ratio is at 2.73.
On April 22, 2025, Cantor Fitzgerald started tracking the stock assigning a Neutral rating and target price of $55.
Jefferies Upgraded its Hold to Buy on December 16, 2024, while the target price for the stock was maintained at $70.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on May 09 ’25 when Hickey Benjamin sold 97 shares for $38.01 per share. The transaction valued at 3,702 led to the insider holds 0 shares of the business.
Hirawat Samit bought 4,250 shares of BMY for $202,215 on Apr 25 ’25. The EVP,Chief Med.Offr.,Drug Dev. now owns 83,513 shares after completing the transaction at $47.58 per share. On Feb 20 ’25, another insider, BOERNER CHRISTOPHER S., who serves as the Chief Executive Officer of the company, bought 2,000 shares for $55.05 each. As a result, the insider paid 110,096 and bolstered with 104,626 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BMY now has a Market Capitalization of 95323144192. As of this moment, Bristol-Myers’s Price-to-Earnings (P/E) ratio for their current fiscal year is 17.59, and their Forward P/E ratio for the next fiscal year is 7.74. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.24. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.00 while its Price-to-Book (P/B) ratio in mrq is 5.48.
Stock Price History:
Over the past 52 weeks, BMY has reached a high of $63.33, while it has fallen to a 52-week low of $39.35. The 50-Day Moving Average of the stock is -3.59%, while the 200-Day Moving Average is calculated to be -13.53%.
Shares Statistics:
A total of 2.04B shares are outstanding, with a floating share count of 2.03B. Insiders hold about 0.10% of the company’s shares, while institutions hold 81.60% stake in the company.
Dividends & Splits
According to the company, the forward annual dividend rate for BMY is 2.44, from 2.44 in the trailing year. Against a Trailing Annual Dividend Yield of 0.05166208
